SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role in both tumor growth promotion and T-cell inactivation. Its allosteric inhibitor SHP099 is known to inhibit cancer cell growth both in vitro and in vivo. However, whether SHP099-mediated SHP2 i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Acta Pharm Sin B
Päätekijät: Zhao, Mingxia, Guo, Wenjie, Wu, Yuanyuan, Yang, Chenxi, Zhong, Liang, Deng, Guoliang, Zhu, Yuyu, Liu, Wen, Gu, Yanhong, Lu, Yin, Kong, Lingdong, Meng, Xiangbao, Xu, Qiang, Sun, Yang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2019
Aiheet:
Original article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437555/
https://ncbi.nlm.nih.gov/pubmed/30972278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2018.08.009
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia